Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Leiszter, Katalin ^a   Sipos, Ferenc ^a   Galamb, Orsolya ^b   Krenács, Tibor ^a   Veres, Gábor ^a   Wichmann, Barna ^b   Furi, István ^b   Kalmár, Alexandra ^a   Patai, Árpá V ^a   Tóth, Kinga ^a   Valcz, Gábor ^b   Tulassay, Zsolt ^a,b   Molnár, Béla ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; OCTREOTIDE; RESTRICTION ENDONUCLEASE; SOMATOSTATIN;

ADULT; ARTICLE; CACO 2 CELL LINE; CANCER PATIENT; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; AGED; CACO-2 CELL LINE; CASE CONTROL STUDY; COLORECTAL TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION;

ADOLESCENT; ADULT; AGED; CACO-2 CELLS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD; COLORECTAL NEOPLASMS; DNA METHYLATION; HUMANS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SOMATOSTATIN;

EID: 84923776218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118332     Document Type: Article

References (69)

1. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20: 157-198. PMID: 10433861
2. Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta. 2003; 1616: 1-84. PMID: 14507421
3. Van Op den Bosch J, Adriaensen D, Van Nassauw L, Timmermans JP. The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review. Regul Pept. 2009; 156: 1-8. doi: 10.1016/j.regpep.2009.04.003 PMID: 19362110
4. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine. 2003; 20: 255-264. PMID: 12721505
5. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion. 2000; 62 Suppl 1: 27-32. PMID: 10940684
6. Low MJ. Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab. 2004; 18: 607-622. PMID: 15533778
7. Grimberg A. Somatostatin and cancer: applying endocrinology to oncology. Cancer Biol Ther. 2004; 3: 731-733. PMID: 15326367
8. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2013.
9. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004; 1014: 121-131. PMID: 15153426
10. Cervia D, Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther. 2007; 116: 322-341. PMID: 17719647
11. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000; 94: 205-210. PMID: 11087998
12. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, et al. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008; 286: 230-237. doi: 10.1016/j.mce.2008.02.002 PMID: 18359151
13. Theodoropoulou M, Stalla GK. Somatostatin receptors: From signaling to clinical practice. Front Neuroendocrinol. 2013; 34: 228-252. doi: 10.1016/j.yfrne.2013.07.005 PMID: 23872332
14. Bousquet C, Guillermet J, Vernejoul F, Lahlou H, Buscail L, et al. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004; 36 Suppl 1: S2-7. PMID: 15077905
15. Leiszter K, Galamb O, Sipos F, Tóth K, Valcz G, et al. [Age-related microscopic and molecular changes of the human colon, and their role in the development of colorectal cancer in elderly people]. Orv Hetil. 2010; 151: 885-892. doi: 10.1556/OH.2010.28882 PMID: 20478809
16. Leiszter K, Galamb O, Sipos F, Spisák S, Tóth K, et al. [The signs of aging in the gastrointestinal tract]. Magy Belorv Arch. 2010; 63: 19-24.
17. Sipos F, Leiszter K, Tulassay Z. Effect of ageing on colonic mucosal regeneration. World J Gastroenterol. 2011; 17: 2981-2986. doi: 10.3748/wjg.v17.i25.2981 PMID: 21799643
18. Leiszter K, Galamb O, Sipos F, Krenács T, Veres G, et al. Sporadic Colorectal Cancer Development Shows Rejuvenescence Regarding Epithelial Proliferation and Apoptosis. PLoS One. 2013; 8: e74140. doi: 10.1371/journal.pone.0074140 PMID: 24098334
19. Galamb O, Spisák S, Sipos F, Tóth K, Solymosi N, et al. Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer. 2010; 102: 765-773. doi: 10.1038/sj.bjc.6605515 PMID: 20087348
20. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, et al. Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2835-2845. doi: 10.1158/1055-9965.EPI-08-0231 PMID: 18843029
21. Galamb O, Wichmann B, Sipos F, Spisák S, Krenács T, et al. Dysplasia-carcinoma transition specific transcripts in colonic biopsy samples. PLoS One. 2012; 7: e48547. doi: 10.1371/journal.pone.0048547 PMID: 23155391
22. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241. doi: 10.3322/caac.21149 PMID: 22700443
23. Adelstein BA, Macaskill P, Turner RM, Katelaris PH, Irwig L. The value of age and medical history for predicting colorectal cancer and adenomas in people referred for colonoscopy. BMC Gastroenterol. 2011; 11: 97. doi: 10.1186/1471-230X-11-97 PMID: 21899773
24. Thomas RP, Hellmich MR, Townsend CM, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev. 2003; 24: 571-599. PMID: 14570743
25. Ferri GL, Adrian TE, Ghatei MA, O'Shaughnessy DJ, Probert L, et al. Tissue localization and relative distribution of regulatory peptides in separated layers from the human bowel. Gastroenterology. 1983; 84: 777-786. PMID: 6186565
26. Parsons JA, Erlandsen SL, Hegre OD, McEvoy RC, Elde RP. Central and peripheral localization of somatostatin. Immunoenzyme immunocytochemical studies. J Histochem Cytochem. 1976; 24: 872-882. PMID: 60436
27. Galamb O, Sipos F, Spisák S, Galamb B, Krenács T, et al. Potential biomarkers of colorectal adenoma-dysplasia-carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and 2 downregulated genes. Cell Oncol. 2009; 31: 19-29. PMID: 19096147
28. Herszényi L, Mihály E, Tulassay Z. [Somatostatin and the digestive system. Clinical experiences]. Orv Hetil. 2013; 154: 1535-1540. doi: 10.1556/OH.2013.29721 PMID: 24058098
29. Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol). 2012; 24: 282-293. doi: 10.1016/j.clon.2011.08.006 PMID: 21907552
30. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy. 2001; 47 Suppl 2: 1-29. PMID: 11549782
31. Grozinsky-Glasberg S, Grossman AB, Korbonits M. The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol. 2008; 286: 238-250. PMID: 18037561
32. Vekemans MC, Urbain JL, Charkes D. Advances in radio-imaging of neuroendocrine tumors. Curr Opin Oncol. 1995; 7: 63-67. PMID: 7696365
33. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002; 13: 451-457. PMID: 12431842
34. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004; 102: 61-85. PMID: 15056499
35. Guillermet-Guibert J, Lahlou H, Pyronnet S, Bousquet C, Susini C. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol. 2005; 19: 535-551. PMID: 16183526
36. Pintér E, Helyes Z, Szolcsányi J. Inhibitory effect of somatostatin on inflammation and nociception. Pharmacol Ther. 2006; 112: 440-456. PMID: 16764934
37. Ferone D, van Hagen PM, Semino C, Dalm VA, Barreca A, et al. Somatostatin receptor distribution and function in immune system. Dig Liver Dis. 2004; 36 Suppl 1: S68-77. PMID: 15077914
38. Reubi JC, Waser B, van Hagen M, Lamberts SW, Krenning EP, et al. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992; 50: 895-900. PMID: 1348240
39. Kwekkeboom DJ, Krenning EP, Kho GS, Breeman WA, Van Hagen PM. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998; 25: 1284-1292. PMID: 9724378
40. Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994; 21: 497-502. PMID: 8082663
41. Vanhagen PM, Markusse HM, Lamberts SW, Kwekkeboom DJ, Reubi JC, et al. Somatostatin receptor imaging. The presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994; 37: 1521-1527. PMID: 7945479
42. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001; 28: 836-846. PMID: 11504080
43. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995; 13: 2012-2015. PMID: 7636542
44. Keller G, Engel JB, Schally AV, Nagy A, Hammann B, et al. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. Int J Cancer. 2005; 114: 831-835. PMID: 15609311
45. Weber C, Merriam L, Koschitzky T, Karp F, Benson M, et al. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery. 1989; 106: 416-422. PMID: 2569769
46. Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, et al. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer. 1998; 77: 115-122. PMID: 9459155
47. Vainas G, Pasaitou V, Galaktidou G, Maris K, Christodoulou K, et al. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res. 1997; 16: 119-126. PMID: 9148872
48. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer. 1995; 71: 97-101. PMID: 7819058
49. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998; 42: 442-447. PMID: 9577356
50. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002; 49: 1245-1250. PMID: 12239914
51. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007; 45: 9-15. PMID: 17187405
52. Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 1995; 75: 23-28. PMID: 7804972
53. Dalm VA, Hofland LJ, Lamberts SW. Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. Mol Cell Endocrinol. 2008; 286: 262-277. PMID: 17942217
54. Savage AP, Calam J, Wood CB, Bloom SR. SMS 201-995 treatment and advanced intestinal cancer: a pilot study. Aliment Pharmacol Ther. 1987; 1: 133-139. PMID: 2979216
55. Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer. 1990; 62: 627-630. PMID: 1977468
56. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer. 1995; 76: 961-966. PMID: 8625221
57. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 1993; 7: 295-299. PMID: 7505187
58. Cascinu S, Catalano V, Giordani P, Baldelli AM, Agostinelli R, et al. Gastrointestinal cancer refractory to chemotherapy: a role for octreotide? Chemotherapy. 2001; 47 Suppl 2: 127-133. PMID: 11275706
59. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996; 56: 1823-1827. PMID: 8620499
60. Miller GV, Farmery SM, Woodhouse LF, Primrose JN. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer. 1992; 66: 391-395. PMID: 1354473
61. Dy DY, Whitehead RH, Morris DL. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res. 1992; 52: 917-923. PMID: 1737355
62. Colucci R, Blandizzi C, Ghisu N, Florio T, Del Tacca M. Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation. Br J Pharmacol. 2008; 155: 198-209. doi: 10.1038/bjp.2008.268 PMID: 18587421
63. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther. 1993; 60: 245-264. PMID: 7912834
64. Goel A, Boland CR. Epigenetics of colorectal cancer. Gastroenterology. 2012; 143: 1442-1460.e1441. doi: 10.1053/j.gastro.2012.09.032 PMID: 23000599
65. Patai AV, Molnár B, Kalmár A, Schöller A, Tóth K, et al. Role of DNA methylation in colorectal carcinogenesis. Dig Dis. 2012; 30: 310-315. doi: 10.1159/000337004 PMID: 22722557
66. Mori Y, Cai K, Cheng Y, Wang S, Paun B, et al. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 2006; 131: 797-808. PMID: 16952549
67. Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 2008; 112: 43-49. PMID: 17999418
68. Jackson K, Soutto M, Peng D, Hu T, Marshal D, et al. Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci. 2011; 56: 125-130. doi: 10.1007/s10620-010-1422-z PMID: 20927589
69. Shi X, Li X, Chen L, Wang C. Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer. Oncol Lett. 2013; 6: 1794-1798.6 PMID: 24260078